Novartis International AG http://www.novartis.com Novartis achieves strong third quarter financial performance and pipeline progress 2011-10-25T08:30:00 CET http://www.novartis.com/newsroom/media-releases/en/2011/1557500.shtml Novartis delivers strong financial results and four major approvals in second quarter of 2011 2011-07-19T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2011/1531819.shtml Novartis makes strong start for the year 2011-04-19T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2011/1507510.shtml Innovation drives Novartis to double-digit growth for 2010 2011-01-27T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2011/1482782.shtml Novartis delivers excellent performance in third quarter: recently launched products generate 20%* of sales; Gilenya approved; Alcon consolidated 2010-10-21T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1453762.shtml Novartis delivers strong financial performance in second quarter, underpinned by increased momentum in innovation 2010-07-15T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1431809.shtml Novartis healthcare portfolio generates strong growth in first quarter of 2010, progress on delivering innovation, growth and productivity 2010-04-20T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1405499.shtml Novartis achieves record results in 2009 as momentum from recently launched products drives growth across its entire healthcare portfolio 2010-01-26T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1377026.shtml Novartis réalise, au troisième trimestre, une excellente performance financière et d'importants progrès dans son pipeline 2011-10-25T08:30:00+01:00 http://www.novartis.com/newsroom/media-releases/fr/2011/1557501.shtml Novartis enregistre, au deuxième trimestre 2011, d'excellents résultats financiers et quatre homologations majeures 2011-07-19T07:00:00+01:00 http://www.novartis.com/newsroom/media-releases/fr/2011/1531820.shtml Résultat opérationnel core en progression de 29% (+30% tcc) à USD 4,2 milliards et marge core en augmentation de 0,4 point de pourcentage (+2,6 points de pourcentage tcc) Novartis démarre l'année en force 2011-04-19T07:00:00+01:00 http://www.novartis.com/newsroom/media-releases/fr/2011/1507511.shtml Novartis: l'innovation entraîne une croissance à deux chiffres en 2010 2011-01-27T07:00:00+01:00 http://www.novartis.com/newsroom/media-releases/fr/2011/1482783.shtml Novartis a réalisé des résultats records en 2009, porté par l'élan des produits lancés récemment qui dopent la croissance de son portefeuille des soins de santé tout entier 2010-01-26T07:00:00+01:00 http://www.novartis.com/newsroom/media-releases/fr/2010/1377019.shtml